Tickerover
Healthcare

WST Stock Analysis

West Pharmaceutical Services, Inc. · current price $336.75 (-2.85% today)

Mixed signals — neither side has the edge here. The thesis lacks a clear edge from current data.
★★★
Average
📊

The six-pillar scorecard

Momentum
51
Drifting higher
price trend
Growth
25
Barely growing
sales & profit growth
Quality
76
High quality
profitability & balance sheet
Valuation
65
Fairly priced
is the price fair?
Sentiment
45
Mixed views
analyst & crowd mood
Risk
65
Moderate risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
GrowthGrowth: 6060Relative strengthRelative strength: 6565Earnings qualityEarnings quality: 8989Analyst consensusAnalyst consensus: 7070Near 52w highNear 52w high: 7575Trend strengthTrend strength: 45451-month momentum1-month momentum: 3030
Margin profileWhat survives each step down the income statement.
GrossGross: 36.8%36.8%OperatingOperating: 22.5%22.5%NetNet: 17.0%17.0%Free cash flowFree cash flow: 13.1%13.1%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: +13.9% vs estimate+14%2026-062026-03: +27.1% vs estimate+27%2026-032025-12: +11.5% vs estimate+12%2025-122025-09: +14.6% vs estimate+15%2025-09
👁

Hype Check

Reading WST’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading WST’s filings…

📣

Latest earnings

LAST EARNINGS West Pharmaceutical Services, Inc. (WST)

Latest earnings

EPS
$1.96 vs $1.71 est · +14.6% vs estimate BEAT
Revenue
$872.3M · +8.4% YoY
Stock reaction (1M)
-0.6%
Beat streak
4 of last 4 quarters
💰

Valuation

P/E
43.3×
Forward P/E
33.9×
PEG
2.97
Price / Sales
7.1×
Price / Book
7.9×
EV / EBITDA
25.9×
Analyst target
$404.73
Target range
$340.00 – $459.00
Implied upside
+20.2%
🩺

Financial health

Gross margin
36.8%
Operating margin
22.5%
Net margin
17.0%
FCF margin
13.1%
Return on equity
19.1%
Debt / equity
0.11
Revenue growth YoY
+13.8%
EPS growth YoY
+18.1%
📈

Technicals

$223.8352-week range$386.00
RSI (14)
39
50-day MA
$349.64
200-day MA
$291.91
ATR (14)
7.24
Beta
1.14
1-month return
-0.6%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$1.96$1.71+14.6%Beat
2025-12-31$2.04$1.83+11.5%Beat
2026-03-31$2.13$1.68+27.1%Beat
2026-06-30$2.37$2.08+13.9%Beat
Beat 4 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.04%
Dividend yield
0.26%
Beta
1.14
📰

Latest news on WST

🔗

Similar stocks in Healthcare

Frequently asked

What is WST's Quant Score?

West Pharmaceutical Services, Inc. (WST) currently has a TickerMover Quant Score of 58/100, rated ★★★ Average. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is West Pharmaceutical Services, Inc. (WST) a buy?

TickerMover does not give buy or sell recommendations. WST scores 58/100 (★★★ Average) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is WST's score updated?

WST's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for WST →